Summary
29.11 0.14(0.48%)09/27/2024
Pfizer Inc. (PFE)
Pfizer Inc. (PFE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.52 | -1.04 | 0.97 | 4.66 | 4.71 | -9.31 | -4.49 | 16,386.19 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 29.11 | |
| Open | 29.02 | |
| High | 29.23 | |
| Low | 28.92 | |
| Volume | 20,912,127 | |
| Change | 0.15 | |
| Change % | 0.52 | |
| Avg Volume (20 Days) | 22,257,575 | |
| Volume/Avg Volume (20 Days) Ratio | 0.94 | |
| 52 Week Range | 25.20 - 34.11 | |
| Price vs 52 Week High | -14.66% | |
| Price vs 52 Week Low | 15.52% | |
| Range | 0.31 | |
| Gap Up/Down | 0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 164,164 | |
| EBIDTA | 9,621,000,192 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.2560 | |
| WallStreet Target Price | 31.37 | |
| Book Value | 16.2840 | |
| Earnings Per Share | -0.0500 | |
| EPS Estimate Current Quarter | 0.5200 | |
| EPS Estimate Next Quarter | 0.4400 | |
| EPS Estimate Current Year | 2.3600 | |
| EPS Estimate Next Year | 2.7600 | |
| Diluted EPS (TTM) | -0.0500 | |
| Revenues | ||
| Profit Marging | -0.0056 | |
| Operating Marging (TTM) | 0.3163 | |
| Return on asset (TTM) | 0.0093 | |
| Return on equity (TTM) | -0.0026 | |
| Revenue TTM | 54,889,000,960 | |
| Revenue per share TTM | 9.7170 | |
| Quarterly Revenue Growth (YOY) | -0.1950 | |
| Quarterly Earnings Growth (YOY) | -0.4340 | |
| Gross Profit (TTM) | 66,233,000,000 | |
| Dividends | ||
| Dividend Share | 1.6500 | |
| Dividend Yield | 0.0600 | |
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 11.6686 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.6451 | |
| Revenue Enterprise Value | 3.4975 | |
| EBITDA Enterprise Value | 21.4072 | |
| Shares | ||
| Shares Outstanding | 5,666,590,208 | |
| Shares Float | 5,657,809,679 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.05 | |
| Institutions (%) | 70.15 | |
09/28 07:30 EST - fool.com
3 Surprisingly Underrated Stocks to Buy Right Now
Bristol Myers Squibb is trading at a significant discount. Moderna has a lot of irons in the fire.
3 Surprisingly Underrated Stocks to Buy Right Now
Bristol Myers Squibb is trading at a significant discount. Moderna has a lot of irons in the fire.
09/27 12:46 EST - zacks.com
PFE vs. NVO: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks presents investors with the better value opportunity right now?
PFE vs. NVO: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks presents investors with the better value opportunity right now?
09/27 10:26 EST - zacks.com
4 High Earnings Yield Stocks That Value Investors Should Buy Now
Unlock your portfolio value by investing in these high-earnings stocks like PPC, PFE, IAG and ASIX.
4 High Earnings Yield Stocks That Value Investors Should Buy Now
Unlock your portfolio value by investing in these high-earnings stocks like PPC, PFE, IAG and ASIX.
09/27 09:31 EST - seekingalpha.com
Pfizer: A 6% Yielding Value Deal
Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines. The oncology business shows promising growth, particularly with products like Xtandi and Lobrena, supporting Pfizer's long-term potential. Pfizer's guidance for FY 2024 EPS has been raised, indicating strong earnings potential and undervaluation by the market.
Pfizer: A 6% Yielding Value Deal
Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines. The oncology business shows promising growth, particularly with products like Xtandi and Lobrena, supporting Pfizer's long-term potential. Pfizer's guidance for FY 2024 EPS has been raised, indicating strong earnings potential and undervaluation by the market.
09/27 09:11 EST - zacks.com
Buy These 4 S&P 500 Year-to-Date Laggards With Solid Near-Term Upside
Four S&P 500 laggards of this year have double-digit upside left for the rest of 2024. These are: CCL, PFE, ZTS, TDY.
Buy These 4 S&P 500 Year-to-Date Laggards With Solid Near-Term Upside
Four S&P 500 laggards of this year have double-digit upside left for the rest of 2024. These are: CCL, PFE, ZTS, TDY.
09/26 18:50 EST - zacks.com
Pfizer (PFE) Rises But Trails Market: What Investors Should Know
Pfizer (PFE) closed the most recent trading day at $28.97, moving +0.14% from the previous trading session.
Pfizer (PFE) Rises But Trails Market: What Investors Should Know
Pfizer (PFE) closed the most recent trading day at $28.97, moving +0.14% from the previous trading session.
09/26 15:41 EST - reuters.com
FDA alerts patients about Pfizer's Oxbryta withdrawal
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's sickle cell disease treatment Oxbryta.
FDA alerts patients about Pfizer's Oxbryta withdrawal
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's sickle cell disease treatment Oxbryta.
09/26 12:41 EST - zacks.com
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.
09/26 11:39 EST - reuters.com
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
09/26 11:31 EST - investopedia.com
Pfizer Recalls All of Its Sickle Cell Disease Treatment Over Safety Concerns
Pfizer (PFE) shares declined Thursday after the drug maker recalled all lots of its sickle cell disease medicine worldwide because of concerns it could lead to severe pain and possibly death in patients.
Pfizer Recalls All of Its Sickle Cell Disease Treatment Over Safety Concerns
Pfizer (PFE) shares declined Thursday after the drug maker recalled all lots of its sickle cell disease medicine worldwide because of concerns it could lead to severe pain and possibly death in patients.
09/26 11:13 EST - reuters.com
EU regulator recommends suspension of Pfizer's sickle cell disease treatment
The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's sickle cell disease drug Oxbryta on Thursday.
EU regulator recommends suspension of Pfizer's sickle cell disease treatment
The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's sickle cell disease drug Oxbryta on Thursday.
09/26 10:41 EST - zacks.com
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.
09/26 08:00 EST - forbes.com
Can Pfizer Stock Rise 2x To $60?
Pfizer stock (NYSE: PFE) is trading at about $30 per share, not far from the lows seen in recent years. Could the stock rise by over 2x in value over the next few years?
Can Pfizer Stock Rise 2x To $60?
Pfizer stock (NYSE: PFE) is trading at about $30 per share, not far from the lows seen in recent years. Could the stock rise by over 2x in value over the next few years?
09/26 07:45 EST - fool.com
2 High-Yield Dividend Stocks That Can Deliver a Lifetime of Passive Income
Verizon and Pfizer offer attractive dividend yields above 5%, supported by strong market positions. Both companies face challenges but have strategies in place to maintain their generous payouts.
2 High-Yield Dividend Stocks That Can Deliver a Lifetime of Passive Income
Verizon and Pfizer offer attractive dividend yields above 5%, supported by strong market positions. Both companies face challenges but have strategies in place to maintain their generous payouts.
09/26 07:25 EST - reuters.com
Slow progress on Pfizer's plan to sell drugs to low-income nations at not-for-profit price, says CEO
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the world's poorest nations at not-for-profit prices, just over two years after it launched.
Slow progress on Pfizer's plan to sell drugs to low-income nations at not-for-profit price, says CEO
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the world's poorest nations at not-for-profit prices, just over two years after it launched.
09/26 04:07 EST - fool.com
3 Ultra-High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
W.P. Carey reduced its dividend after spinning off its office properties last year but still offers an ultra-high yield. Pfizer's been raising its dividend every year since 2009, and an unprecedented number of recently launched drugs could help it rise much further.
3 Ultra-High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
W.P. Carey reduced its dividend after spinning off its office properties last year but still offers an ultra-high yield. Pfizer's been raising its dividend every year since 2009, and an unprecedented number of recently launched drugs could help it rise much further.
09/25 17:36 EST - marketwatch.com
Pfizer yanks sickle-cell treatment worldwide after possible link to deaths
The benefits of Oxbryta no longer outweigh the risks, Pfizer says.
Pfizer yanks sickle-cell treatment worldwide after possible link to deaths
The benefits of Oxbryta no longer outweigh the risks, Pfizer says.
09/25 17:17 EST - reuters.com
Pfizer withdraws sickle cell disease treatment from all markets
U.S. drugmaker Pfizer said on Wednesday it would voluntarily withdraw its therapy Oxbryta, used for the treatment of sickle cell disease, in all markets where it is approved.
Pfizer withdraws sickle cell disease treatment from all markets
U.S. drugmaker Pfizer said on Wednesday it would voluntarily withdraw its therapy Oxbryta, used for the treatment of sickle cell disease, in all markets where it is approved.
09/25 17:00 EST - businesswire.com
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickl.
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickl.
09/25 10:05 EST - fool.com
1 Ultra-High-Yield Healthcare Stock to Buy Hand Over Fist and 1 to Avoid
Pfizer and Medical Properties Trust have dividend yields well above 5%. Both companies have had their share of issues lately.
1 Ultra-High-Yield Healthcare Stock to Buy Hand Over Fist and 1 to Avoid
Pfizer and Medical Properties Trust have dividend yields well above 5%. Both companies have had their share of issues lately.